1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    



























































































































    Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma | American Journal of Neuroradiology  
    



















    































    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticleBrain

  
      
Open Access

  
      
Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma
  
    	
B.M. Ellingson, S. Sahebjam, H.J. Kim, W.B. Pope, R.J. Harris, D.C. Woodworth, A. Lai, P.L. Nghiemphu, W.P. Mason and T.F. Cloughesy

  
    	
American Journal of Neuroradiology April 2014,  35 (4) 673-679; DOI: https://doi.org/10.3174/ajnr.A3748 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. 1.↵


    Central Brain Tumor Registry of the United States. CBTRUS Statistical Report Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2006. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf. Accessed January 2013
  2. 2.↵


    1. Stupp  R, 
    2. Mason  WP, 
    3. van den Bent  MJ, 
    4. et al
    . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96
    CrossRefPubMedWeb of Science
  3. 3.↵


    1. Wong  ET, 
    2. Hess  KR, 
    3. Gleason  MJ, 
    4. et al
    . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572–78
    Abstract/FREE Full Text
  4. 4.↵


    1. Plate  KH, 
    2. Breier  G, 
    3. Risau  W
    . Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994;4:207–18
    CrossRefPubMedWeb of Science
  5. 5.↵


    1. Millauer  B, 
    2. Shawver  LK, 
    3. Plate  KH, 
    4. et al
    . Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576–79
    CrossRefPubMed
  6. 6.↵


    1. Holash  J, 
    2. Maisonpierre  PC, 
    3. Compton  D, 
    4. et al
    . Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–98
    Abstract/FREE Full Text
  7. 7.↵


    1. Pope  WB, 
    2. Young  JR, 
    3. Ellingson  BM
    . Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011;11:336–44
    CrossRefPubMed
  8. 8.↵


    1. Leu  K, 
    2. Pope  WB, 
    3. Cloughesy  TF, 
    4. et al
    . Imaging biomarkers for anti-angiogenic therapy in malignant gliomas. CNS Oncology 2013;2:33–47
    CrossRefPubMed
  9. 9.↵


    1. Pope  WB, 
    2. Kim  HJ, 
    3. Huo  J, 
    4. et al
    . Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182–89
    CrossRefPubMedWeb of Science
  10. 10.↵


    1. Pope  WB, 
    2. Lai  A, 
    3. Mehta  R, 
    4. et al
    . Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 2011;32:882–89
    Abstract/FREE Full Text
  11. 11.↵


    1. Ellingson  BM, 
    2. Bedekar  DP, 
    3. Malkin  MG, 
    4. et al
    . Hybrid functional diffusion and perfusion maps for evaluation of gliomas. In: Proceedings of the 17th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Honolulu, Hawaii. April 18–24, 2009;17:1000
  12. 12.↵


    1. Ellingson  BM, 
    2. Cloughesy  TF, 
    3. Lai  A, 
    4. et al
    . Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:1151–61
    Abstract/FREE Full Text
  13. 13.↵


    1. Ellingson  BM, 
    2. Cloughesy  TF, 
    3. Lai  A, 
    4. et al
    . Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2011;105:91–101
    CrossRefPubMed
  14. 14.↵


    1. Ellingson  BM, 
    2. Cloughesy  TF, 
    3. Lai  A, 
    4. et al
    . Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med 2012;67:237–45
    CrossRefPubMed
  15. 15.↵


    1. Kothari  PD, 
    2. White  NS, 
    3. Farid  N, 
    4. et al
    . Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. AJNR Am J Neuroradiol 2013;34:1752–57
    Abstract/FREE Full Text
  16. 16.↵


    1. White  NS, 
    2. McDonald  CR, 
    3. Farid  N, 
    4. et al
    . Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using “restriction spectrum imaging”: quantitative comparison with high B-value DWI and ADC. AJNR Am J Neuroradiol 2013;34:958–64, S1
    Abstract/FREE Full Text
  17. 17.↵


    1. Andre  JB, 
    2. Lu  S, 
    3. Spearman  K, 
    4. et al
    . Peritumoral apparent diffusion coefficient as a metric of response in patients with recurrent glioblastoma multiforme treated with bevacizumab and irinotecan. NRJ 2008;21:350–61
  18. 18.↵


    1. Gerstner  ER, 
    2. Frosch  MP, 
    3. Batchelor  TT
    . Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010;28:e91–93
    FREE Full Text
  19. 19.↵


    1. Pope  WB, 
    2. Qiao  XJ, 
    3. Kim  HJ, 
    4. et al
    . Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108:491–98
    CrossRefPubMed
  20. 20.↵


    1. Pope  WB, 
    2. Mirsadraei  L, 
    3. Lai  A, 
    4. et al
    . Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol 2012;33:1059–64
    Abstract/FREE Full Text
  21. 21.↵


    1. Lucio-Eterovic  AK, 
    2. Piao  Y, 
    3. de Groot  JF
    . Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589–99
    Abstract/FREE Full Text
  22. 22.↵


    1. Keunen  O, 
    2. Johansson  M, 
    3. Oudin  A, 
    4. et al
    . Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749–54
    Abstract/FREE Full Text
  23. 23.↵


    1. Padhani  AR, 
    2. Liu  G, 
    3. Mu-Koh  D, 
    4. et al
    . Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102–25
    PubMedWeb of Science
  24. 24.↵


    1. Gerstner  ER, 
    2. Chen  PJ, 
    3. Wen  PY, 
    4. et al
    . Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 2010;12:466–72
    Abstract/FREE Full Text
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma
  
    	
B.M. Ellingson, S. Sahebjam, H.J. Kim, W.B. Pope, R.J. Harris, D.C. Woodworth, A. Lai, P.L. Nghiemphu, W.P. Mason, T.F. Cloughesy

  
    	
 American Journal of Neuroradiology Apr 2014, 35 (4) 673-679; DOI: 10.3174/ajnr.A3748 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    

  

    
 Related Articles
  • No related articles found.
 Cited By...
 More in this TOC Section
 Similar Articles

  



  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement